Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000214923 | SCV000273169 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-08-08 | criteria provided, single submitter | clinical testing | The c.212delA pathogenic mutation, located in coding exon 2 of the CDKN2A gene, results from a deletion of one nucleotide at nucleotide position 212, causing a translational frameshift with a predicted alternate stop codon (p.N71Tfs*75). This alteration occurs at the 3' terminus of CDKN2A gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 86 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). This alteration has been observed in at least one individual with a personal and/or family history that is consistent with CDKN2A -related disease (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Baylor Genetics | RCV003475002 | SCV004212528 | likely pathogenic | Melanoma and neural system tumor syndrome | 2022-07-28 | criteria provided, single submitter | clinical testing |